Genscript Biotech Addresses Share Price Volatility, Confirms Stable Operations Ahead of Board-Lot Adjustment

Bulletin Express11-03

Genscript Biotech Corporation has issued a voluntary announcement after recording recent unusual movements in its share price. The Board attributes heightened speculation to misinterpretations of the company’s previously disclosed plan to change its board-lot size from 2,000 to 1,000 shares, effective 14 October 2026.

Key timetable • 14 Oct 2026, 09:00: Existing counter (2,000-share lots) converted to 1,000-share lots; temporary 2,000-share counter opens; first day of parallel trading. • 04 Nov 2026, 16:10: Temporary 2,000-share counter closes; final day of parallel trading. • 06 Nov 2026, 16:30: Deadline for free exchange of old 2,000-share certificates for new 1,000-share certificates.

Management reiterated that the company’s business and financial condition remain normal, with no material changes following its investor day on 30 October 2026. After reasonable enquiry, the Board stated it is unaware of any information that would explain the recent share-price fluctuations and confirmed there is no inside information requiring disclosure under Part XIVA of the Securities and Futures Ordinance.

Shareholders and potential investors are urged to interpret recent market movements in the context of the scheduled board-lot change and to exercise due caution in dealing with the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment